Author Title [ Type(Desc)] Year
Filters: Author is Kersten, Marie José  [Clear All Filters]
Journal Article
Mank APM, Schoonenberg C, Bleeker K, Heijmenberg S, de Heer K, van Oers MHJ, Kersten MJosé. Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care. Leuk Lymphoma. 2014:1-20.
Persoon S, Kersten MJosé, Buffart LM, Slagmolen GVander, Baars JW, Visser O, Manenschijn A, Nollet F, Chinapaw MJM. Health-related physical fitness in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation. J Sci Med Sport. 2016.
Brink M, Meeuwes FO, van der Poel MWM, Kersten MJosé, Wondergem M, Mutsaers PGNJ, Böhmer LH, Woei-A-Jin FJSherida, Visser O, Oostvogels R, et al. Impact of Etoposide and ASCT on Survival Among Patients <65 years With Stage II-IV PTCL; a Population-Based Cohort Study.. Blood. 2022.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.
Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJosé, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, et al. Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2014.
Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SRonan, van Besien K, Wagner-Johnston ND, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560-572.